Biotech: Page 49

PharmaVoice Team/PharmaVoice

It's All About Changing Practice

It’s All About Changing Practice Each and every step along the drug-development path must focus on the end game — to define the place of a new drug in practice, and then to communicate the data clearly and consistently using all available channels. But can companies make themselves heard in th...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Creating a Guidance System for Life-Science Brands

Creating a Guidance System for Life-Science Brands While meaningful biomedical research depends on proteomics, genetics, and genomics tools, their ultimate application also will depend on successful commercialization and marketing tools. Mark Stinson President ...
By PharmaVoice Team • Jan. 2, 2008
Explore the Trendline➔

Stock via Getty Images

Trendline

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff
PharmaVoice Team/PharmaVoice

Personalized Medicine: Our Industry's Next Great Leap Forward

Personalized Medicine: Our Industry’s Next Great Leap Forward Marketing Personalized medicine will drive medicine to become much more of a science than an art. And with that change, there will be many necessary fundamental changes to how our industry markets these innovations. Ri...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Recruitment: To Centralize or Decentralize? This is the Question.

Recruitment: To Centralize or Decentralize? This is the Question. Liz Moench President and CEO Patient and Investigator Recruitment In many people’s minds, centralized recruitment often symbolizes big money and big studies. But in actuality, nothing could...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Strategic Phase II Planning -- More Important Than Ever for the Biotech Industry

Strategic Phase II Planning — More Important Than Ever for the Biotech Industry Lukas Makris, Ph.D. CEO Phase II programs should not only be judged on how well the objectives were met, but on how well they might predict the Phase III outcome. The biotechnology industr...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness

Marketing Strategies for Emerging Companies: Lessons from the Maine Wilderness for Biotech and Biopharma I do not consider a sale complete until the goods are worn out and the customer (sic) is still satisfied.” When Leon Leonwood Bean posted those words in his humble Maine store in 1916 he wa...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Branding Your Company -- Right from the Start

Branding Your Company — Right from the Start Executives of emerging biotech companies face myriad challenges. While they may certainly understand the value of branding and marketing, those functions may command less of their attention during the early stages of company development than the challe...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

A Robust Future for Phase IV Trials

A Robust Future for Phase IV Trials May 2005 VIEW on Biotechnology Clinical Trials Dimensional HealthCare Inc., Cedar Knolls, N.J., designs, implements, and provides community-based research to the pharmaceutical and medical-device industries, focusing on the design and implementation of la...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Table of Contents

Table of contents Letter from the Editor The Forum Biotech: The Perfect Storm — A relatively more favorable funding environment, cutting-edge technologies, and a strong position at the partnership table have many of today’s biotechnology companies in a position for success. Company Listing by Top...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Next BIG Thing in EDC

The Next BIG Thing in EDC The most compelling evidence for the argument that electronic data capture (EDC) is entering the mass adoption phase of its technology life cycle is the rate at which sponsors and CROs are internalizing the development processes. Technology transfer or in-licensing o...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Giving Birth to a Healthy Brand

Joseph Doyle, R.Ph. Chief Branding and Strategy Officer Giving Birth to a Healthy Brand the promotional mix Closely aligning clinical and marketing strategies early in development is the way to ensure that a brand will be born healthy. It seems that no matter what the br...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

On the Calendar

May 16-17 Global Clinical Trials Hyatt Regency Jersey City, Jersey City, N.J. For more information, contact Caria Badenhorst, Marcus Evans, at 246-417-5321, e-mail [email protected], or visit marcusevans.com. May 16-17 5th Annual Sample Accountability Hyatt Regency Princeton, Princeton, N....
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Table of Contents

On the Cover Culture of compliance: Cutting through the confusion To be compliant with the many regulations and guidances that apply to the marketing of prescription products, companies need to create a culture of compliance that fosters and promotes an ethical atmosphere and compliant behavior. ...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Art of the Deal

The biotech industry is in a much stronger position now than it was in its early days, and today biotech companies enjoy a prominent seat at the negotiation table. Biotech companies, especially those with products, are asking for true collaboration instead of relying on licensing deals. The days ...
By Denise Myshko • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

What's on Your Mind -- Opinions

Opinions More on Leadership Development PharmaVOICE received such an overwhelming response to our leadership development opinion question — how executives throughout the industry develop leaders — for the April issue, we are pleased to publish additional insights on this hot topic. Entrepreneuria...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

On the Calendar

February 15-17 WCBF Six Sigma in Chemicals & Pharmaceuticals Hyatt Regency Dallas, Dallas For more information, contact Louise Gosling, WCBF Six Sigma Solutions, at 44-14-83 76-0883, e-mail [email protected], or visit wcbf.com. February 15-18 18th Annual DIA Electronic Document Manageme...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Cover

PharmaVOICE The Forum for the Industry Executive Year In Preview: 2005 More than 100 experts talk about the industry’s future www.pharmavoice.com December 2004 Special Issue Volume 4 Number 12 Download PDF
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Table of Contents

Contents Kristine Nash-Wong, Marketing Manager at HealthMedia, speaks about reputation enhancement. Dr. Thomas Wicks, VP of Regulatory Affairs at Odyssey Pharmaceuticals, talks about continuing treatment innovation while limiting costs. Scott Szwast, Sector Marketing Manager at UPS Supply Chain S...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Letter from the Editor

2005 Year In Preview Taren Grom In keeping with PharmaVOICE’s mission of providing insightful and provocative commentary on the business practices, strategies, and services that affect the life cycle of products from molecule through market, it is our pleasure to publish the first annual Year in ...
By Taren Grom • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Introduction

The Pulse of the Industry By Taren Grom This first annual PharmaVOICE Year in PreVIEW is designed to provide an overview of the challenges and trends expected to impact the life-sciences industry in the coming year and beyond. For this special forum, a distinguished list of more than 100 industry...
By Taren Grom • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Business Models

Turett. The pharmaceutical industry needs to resolve multiple bipolarities: being a business and being a public utility; being doctor-focused and being consumer-focused; and being about medical innovation and being about marketing. The industry has begun a process of self-reinvention that in 2005...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Medical Education

Medical Education Nash-Wong. Last year’s predictions on regulatory changes had us believing medical education was a thing of the past. Not so, if one considers the fact that physicians continue to attend educational meetings, despite limited food budgets and a ban on spouses. So rather than forec...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Multifunctional Teams

Multifunctional Teams Wilson. Historically, the pharmaceutical industry has faced two hurdles: achieving product registration and securing reimbursement. Today, demonstrating product value is becoming a much stronger issue. It’s not just a matter of product price, but the impact on total cost of ...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Technology

Technology Cauwenbergh. Ideally, predictive tools, including assays, computer modeling techniques, and biomarkers could shorten development time, reduce the cost of development, and increase the accuracy of diagnosis, making sure that the right patient gets the right drug because of proper diagno...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Risk Management

Risk Management Turett. The term risk management implies a defensive, prepare-for-the-worst strategy. While defensive preparation is certainly important, taking a fresh look at conducting business in a “patient-first” manner will reduce the need to implement a defensive approach. In other words, ...
By PharmaVoice Team • Jan. 2, 2008